This chapter presents a series of multiple choice questions and answers on nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). It commences with a discourse on which features do the NLPHL and classical Hodgkin lymphoma (cHL) differ, and ends with the discussion on the next diagnostic or therapeutic step for the patient with cervical and mediastinal lymphadenopathy. The chapter tabulates the staining characteristics of the NLPHL and cHL. In cHL, combined-modality treatment (CMT) was shown to result in a superior clinical outcome as compared with RT alone and is thus considered the standard of care for early favorable stages. It also tabulates the rituximab for the treatment of NLPHL.